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Abstract
Background: Interferon (IFN)-a receptor 1 (ifnar1) and suppressor of cytokine signaling 1 (socs1) transcription levels
were quantified in peripheral blood mononuclear cells (PBMC) of 59 patients infected with hepatitis C virus (HCV)
and 17 non-infected individuals. Samples were obtained from patients infected with HCV that were either
untreated or treated with IFN-a2 plus ribavirin for 1 year and divided into responders and non-responders based
on viral load reduction 6 months after treatment. Ifnar1 and socs1 transcription was quantified by real-time RT-PCR,
and the fold difference (2
-ΔΔCT) with respect to hprt housekeeping gene was calculated.
Results: Ifnar1 transcription increased significantly in HCV-infected patients either untreated (3.26 ± 0.31),
responders (3.1 ± 0.23) and non-responders (2.18 ± 0.23) with respect to non-infected individuals (1 ± 0.34; P =
0.005). Ifnar1 transcription increased significantly (P = 0.003) in patients infected with HCV genotypes 1a (4.74 ±
0.25) and 1b (2.81 ± 0.25) but not in 1a1b (1.58 ± 0.21). No association was found of Ifnar1 transcription with
disease progress, initial viral load or other clinical factors. With respect to socs1 transcription, values were similar for
non-infected individuals (1 ± 0.28) and untreated patients (0.99 ± 0.41) but increased in responders (2.81 ± 0.17)
and non-responder patients (1.67 ± 0.41). Difference between responder and non-responder patients was not
statistically significant. Socs1 transcription increased in patients infected with HCV genotypes 1a and 1b (2.87 ± 0.45
and 2.22 ± 0.17, respectively) but not in 1a1b (1.28 ± 0.40). Socs1 transcript was absent in three patients infected
with HCV genotype 1b. A weak correlation between ifnar1 and socs1 transcription was found, when Spearman’s
correlation coefficient was calculated.
Conclusion: Our results suggest that HCV infection may up-regulate ifnar1 transcription. HCV genotypes differ in
their capacity to affect ifnar1 and socs1 transcription, as well as in the ability to evade the antiviral response.
Background
Hepatitis C virus (HCV) is a public health concern
worldwide and a major cause of chronic liver inflamma-
tion, cirrhosis and hepatocellular carcinoma (HCC) [1].
In Mexico, the prevalence of HCV is ~1.4% in the open
population and 35% in patients with active hepatitis [2].
H C Vi sas i n g l e - s t r a n d e dp o s i t i v eR N Av i r u st h a t
codes for a precursor polyprotein, which is processed
i n t o1 0a c t i v ep r o t e i n s :C ,P 7 ,E 1 ,E 2 ,N S 2 ,N S 3 ,N S 4 A ,
N S 4 B ,N S 5 Aa n dN S 5 B .D u et oh i g hg e n e t i cd i v e r s i t y ,
HCV is classified according to several genotypes and
subtypes, which differ in geographic distribution, viru-
lence and sensitivity to medical treatment [3]. In Mex-
ico, the prevalence of genotype 1 ranges from 30 to
87.5%, with a predominance of subtypes 1b and 1a.
Genotypes 2 and 3 are less frequent and genotypes 4-6
are unusual in Mexican subjects [4,5].
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tion of pegylated IFN-a plus ribavirin for 24-48 weeks.
However, almost 50% of treated patients do not respond
to interferon therapy and, thus, are not able to clear the
virus infection [3,6]. IFN-a activity is mediated by its
high-affinity binding to IFN-a receptor (IFNAR) and
subsequent induction of the Jak-Stat signaling pathway
that activates transcription of >100 genes that establish
an antiviral state in the cells [7].
The response to IFN-a therapy is influenced by HCV
factors such as viral genotype, antigenic variability, viral
susceptibility to IFN-induced proteins, expression of
viral proteins that counteract IFN actions, etc. [8].
Indeed, HCV has developed several strategies to evade
adaptive immune response and to block the action of
effector proteins induced by IFN [9,10].
Some host genetic factors also affect the response to
IFN-a therapy. In addition, the presence of anti-IFN-a
antibodies and soluble forms of human IFNAR in
plasma have been implicated in the resistance to IFN-a
therapy in patients with chronic HCV infection [10-13].
Absence of or low intrahepatic transcription of ifnar1 is
also related to a poor response to IFN-a and severity of
liver disease [13-15]. Consequently, high expression of
ifnar1 in liver and PBMCs of patients with HCV have
been associated with efficient IFN-induced antiviral
response and clearance of virus infection [16].
Virus infection induces the expression of negative reg-
ulators of the IFN signaling pathway such as the sup-
pressor of cytokine signaling 1 (socs1), which associates
with and inactivates Jak kinase, inhibiting the phosphor-
ylation of both IFNAR and Stat proteins [17,18] and
downregulating the transcription of IFN-stimulated
genes [19]. Conversely, transfection of HCV core protein
in mouse liver silences socs1 transcription leading to
permanent activation of the Jak-Stat signaling pathway
[20]. Transcriptional silencing of socs1 gene has been
found in the liver of patients with chronic HCV infec-
tion and HCC [21].
Based on the significance of ifnar1 and socs1 genes in
activation/downregulation of IFN-mediated antiviral
response, we developed real-time RT-PCR assays to
quantify ifnar1 and socs1 transcription in PBMCs of
HCV-infected patients, testing their usefulness in the
analysis of patients’ response to IFN-a therapy.
Results
Sixty-five HCV-infected patients were initially sampled.
Samples of six patients were discarded because of their
low leukocyte counts. The remaining patients were 35
females and 24 males with an age range of 20-69 years;
15/59 infected patients presented cirrhosis, 44 had active
hepatitis, and none presented clinical data attributable
to HCC.
Viral loads were monitored in all infected patients at 6
months after the end of treatment. Thirty-one infected
and IFN-treated patients presented sustained viral
response (responders, R) and cleared the virus infection
and remained negative to viral genome detection. Seven-
teen IFN-treated patients did not reduce their viral loads
(non-responders, NR). Eleven infected patients were
analyzed prior to treatment and were considered
untreated (U).
Real-time RT-PCR assay validation
A real-time RT-PCR assay was developed to quantify
ifnar1 transcription based on the use of a TaqMan
probe. To validate the detection method, we verified the
amplification efficiencies of ifnar1 and the housekeeping
gene hprt using RNA from human HeLa cell line. The
differences of threshold cycle (ΔCT) between ifnar1 and
hprt (CTifnar1-CThprt) at several mRNA concentrations
gave a lineal slope of 0.0167 (Figure 1), indicating that
both genes have proportional expression efficiencies
within the dynamic range of 1-16 ng.
For the analysis of socs1 transcription, a quantitative
method of real-time RT-PCR based on the use of SYBR
Green was developed. Validation was performed by com-
paring the amplification efficiencies for socs1 and hprt
genes in HeLa cells. Dynamic range for socs1 and hprt
ΔCT values was 1.6-15.5 ng, giving a lineal slope of -0.17
(Figure 2A). Thus, hprt can be also used for the relative
quantification of socs1 and permits to compare socs1 and
ifnar1 transcription. The specificity of SYBR Green assay
was corroborated by the dissociation curves that only
Figure 1 Validation of ifnar1 real-time RT-PCR. Ifnar1 detection
assay was based on the use of TaqMan probes. Validation curves
were performed with RNA extracted from HeLa cells, and the
threshold cycle difference (ΔCT) between ifnar1 and the constitutive
endogenous gene hprt was calculated and drawn with respect to
RNA concentration. Slope value (y) indicates that hprt can be used
for relative quantification of ifnar1 transcription.
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for socs1 and hprt amplification products (Figure 2B).
Ifnar1 transcription in HCV-infected patients
For optimal relative quantification of ifnar1 mRNA the
fold difference of ΔCT (2
-ΔΔCT ± SD) between study
groups were calculated. Resulting values were 1 ± 0.34
for uninfected individuals, 3.26 ± 0.31 for infected
untreated patients, 3.1 ± 0.23 for infected IFN-treated
responder patients and 2.18 ± 0.23 for non-responder
patients (Figure 3A). These results indicate that ifnar1
transcription increased significantly (P = 0.005) due to
HCV infection but was not significant with respect to
the patients’ viral response to IFN therapy.
We analyzed if viral load, ALT level or grade of liver
disease was associated with ifnar1 transcription, but no
correlation was found between ifnar1 transcription and
any of these clinical factors (data not shown).
Association of ifnar1 transcription and HCV genotypes
Infected patients were grouped according to their HCV
genotype 1a (n =6 ) ,1 b( n = 47) and 1a1b (n =6 ) .
Other genotypes were not found. An association of
ifnar1 transcription with viral genotype was found, thus
the fold difference values for uninfected group were 1 ±
0.34, for genotype 1a 4.74 ± 0.25, for 1b 2.81 ± 0.25,
and for 1a1b 1.58 ± 0.21 (Figure 3B). Increased tran-
scription was statistically significant for genotypes 1a
and 1b (P = 0.003) but not for 1a1b.
Figure 2 Validation of socs1 real-time RT-PCR. A. Socs1 detection
assay was based on the use of Sybr Green. Validation curves were
performed with RNA extracted from HeLa cells, and the threshold
cycle (ΔCT) difference between socs1 and hprt was calculated and
drawn with respect to RNA concentration. Slope value (y) indicates
that hprt can be used for relative quantification of socs1
transcription. B. Assay specificity was corroborated by means of the
dissociation curves. Peaks correspond to the melting temperatures
for socs1 and hprt genes.
Figure 3 Ifnar1 relative transcription. A. Relative quantification of
ifnar1 transcription was determined by real-time RT-PCR and the
fold difference (2
-ΔΔCt) between study groups were calculated: non-
infected controls (NI); untreated (U), responders (R) and non-
responder (NR) patients. B. ifnar1 transcription in patients classified
according to HCV genotype 1a, 1b and 1a1b (NI, non-infected).
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Socs1 transcription was analyzed in 15 non-infected
individuals and 50 HCV-infected patients. These cor-
responded to nine untreated, 29 responders and 12
non-responder patients. The calculated fold differ-
ences between study groups were 1 ± 0.28 for non-
infected individuals, 0.99 ± 0.41 for untreated subjects,
2.81 ± 0.17 for responders and 1.67 ± 0.41 for non-
responders (Figure 4A). An apparent difference
between responder patients and all other groups was
noticed, but this was not statistically significant. No
correlation was found between socs1 transcription and
ALT levels, disease progression or viral loads before
treatment.
Association of socs1 transcription and HCV genotypes
For socs1 analysis, infected patients were grouped
according to their HCV genotype 1a (n =5 ) ,1 b( n =
41) and 1a1b (n =4 ) .Socs1 transcription increased in
patients infected with HCV genotype 1a and 1b (2.87 ±
0.45 and 2.22 ± 0.17, respectively) but not in patients
with genotype 1a1b (1.28 ± 0.41; Figure 4B). These dif-
ferences were not statistically significant. Socs1 tran-
scripts were undetectable in 3/41 patients infected with
HCV genotype 1b.
Correlation between ifnar1 and socs1 gene transcription
The Spearman’s correlation coefficient between
ifnar1 and socs1 transcription was calculated. No cor-
relation was found if patients were classified accord-
ing with their response to treatment (r =0 . 0 1 ,P =
0.9; Figure 5A). Instead, there was a weak inverse
Figure 4 Socs1 relative transcription. A. Relative quantification of
socs1 transcription was determined by real-time RT-PCR and the
fold differences (2
-ΔΔCt) between study groups were calculated: non-
infected controls (NI), untreated (U), responders (R) and non-
responder (NR) patients. B. Socs1 transcription in patients classified
according to HCV genotype 1a, 1b and 1a1b (NI, non-infected).
Figure 5 Correlation between ifnar1 and socs1 gene
transcription. Spearman’s correlation coefficient (r) between ifnar1
and socs1 ΔCT values was calculated. A. Analysis done with patients
classified according with their response to treatment; non-infected
controls (NI), untreated (U), responders (R) and non-responders (NR).
B. Analysis done with patients grouped by HCV genotype.
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that was associated with virus genotype (r = -0.22,
P =0 . 1 ;F i g u r e5 B ) .
Discussion
We undertook this study to evaluate the association of
ifnar1 and socs1 transcription with HCV infection and
response to IFN therapy. We first validated the detec-
tion methods for both ifnar1 and socs1 transcripts and
compared their amplification efficiencies with respect to
t h es a m eh o u s e k e e p i n gg e n ehprt. Based on their pro-
portional expression within the dynamic range of 1-
15 ng, we concluded that hprt can be used as a refer-
ence gene for relative quantification of ifnar1 and socs1
transcription as well as for comparative analysis of both
genes, even though we used different strategies for their
detection.
Results showed increased ifnar1 transcription in all
groups of HCV-infected patients: 3.2- and 3.1-fold in
the group of untreated and responder patients and only
2.1-fold in non-responder patients compared with non-
infected individuals (P = 0.005). These results suggest
that ifnar1 transcription increased due to HCV infection
but was not significant for determining the association
with response to treatment. We analyzed whether viral
load, ALT level or grade of liver disease was associated
with ifnar1 transcription, but no correlation was found
between ifnar1 transcription and any of these clinical
factors.
An association of ifnar1 transcription with viral geno-
type was found. Indeed, ifnar1 transcription was higher
in infected patients than in non-infected individuals,
4.7-fold in patients with HCV genotype 1a, but only 2.8-
and 1.6-fold in patients with genotypes 1b and 1a1b,
respectively (P = 0.003). Viral genotype 1b is frequently
associated with advanced liver disease and lack of viral
response to IFN therapy; and the latter is further asso-
ciated with reduced expression of IFNAR receptors, low
functionality of the Jak-Stat pathway and reduced
expression of proteins with antiviral activities. This is
important because 14/15 patients with cirrhosis had
HCV genotype 1b and 8/17 non responder patients had
1b genotype. Controversially, patients infected with
HCV genotypes 1a1b had the lowest ifnar1-mRNA
levels, but most of them responded to treatment. These
results are not conclusive because of the scarce number
of patients with genotypes 1a1b in this study.
Significant reduction of ifnar1 mRNA and protein
levels in liver has been associated with high hepatitis
activity, advanced liver fibrosis, poor response to IFN-a,
and high viral load [15,22]. We and other authors car-
ried out the quantification of ifnar1 in blood cells
b e c a u s ei ti sl e s si n v a s i v ea n dm i g h tb ec o r r e l a t e dw i t h
virus clearance in serum, mononuclear cells and
probably the liver. Previous studies have analyzed the
association of ifnar1 t r a n s c r i p t i o ni nP B M C sw i t h
response to IFN therapy and reduction of serum viral
loads using endpoint RT-PCR, but no correlation was
found with viral clearance in liver [16,23]. Compared
with those studies, our work improves ifnar1 quantifica-
tion and sensitivity because of the use of real-time RT-
PCR. However further experiments are required to cor-
relate or not with the clearance of liver infection.
Experimental studies have shown that deficient pro-
duction of ifnar1 transcripts may be one of the primary
defects that lead to the lack of a response to IFN-a in
HCV-infected patients [14,15]. Therefore, we also ana-
lyzed socs1 based on the hypothesis that socs1 contri-
butes to the lack of response by down-regulating the
Jak-Stat pathway and, consequently, ifnar1 transcription.
At respect, socs1 gene promoter possesses transcription
factor binding sites for STAT1, which both are activated
by and initiate the negative feedback of the IFN-signal-
ing pathway [24,25]. Our results suggested that the
major inducer of socs1 transcription was exogenous
IFN-a treatment but not virus infection as occurred
with ifnar1 transcription. The levels of socs1 transcrip-
tion were similar in non-infected individuals and
infected patients who were not yet under IFN treatment,
whereas in patients submitted to IFN-a treatment the
level of socs1 transcription was higher. Although IFN
therapy increased socs1 transcription, the effect was
m o r en o t a b l ei nr e s p o n d e r st h a ni nn o n - r e s p o n d e r
patients (Figure 4A). This is contrary to our initial
hypothesis, but it is noteworthy that analysis of socs1
transcription can be used to pursue the response to
treatment in other studies that include a higher number
of patients.
We analyzed whether ifnar1 and socs1 transcription
were associated, by calculating the Spearman’s correla-
tion coefficient. There was no association between
ifnar1 and socs1 genes when patients were grouped on
the basis of their response to treatment. However, these
genes presented a weak inverse correlation, the lower
ifnar1 the higher socs1,w h e np a t i e n t sw e r ec l a s s i f i e db y
viral genotype.
The role of socs1 in liver disease has been analyzed in
mouse socs1
-/+ submitted to chemically induced fibrosis,
which in addition to socs1 reduction produces fatty
degeneration of hepatic cells, macrophage infiltration
and increases IL-6, TGF-b and IFN-b secretion. Those
data indicate that liver reduction of socs1 increased with
liver inflammation and fibrosis [26].
It is noteworthy that socs1 transcripts were absent in 3/
41 patients infected with genotype 1b. Undetectable socs1
transcription is a frequent finding in liver biopsies of
patients with HCC [21]. In addition, socs1 has been asso-
ciated with tumor suppression because it reduces the
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tion [27-29] and silencing of socs1 gene leads to tumor
progression [26]. In our study, none of the patients with
undetectable socs1 transcripts presented cirrhosis or
HCC; however, these results suggest that silencing of
socs1 transcription started early during HCV infection.
Conclusions
Our results suggest that HCV infection may up-regulate
ifnar1 transcription. Viral genotypes differ in their capa-
city to affect ifnar1 and socs1 transcription; as well as in
their ability to avoid the antiviral response. Further stu-
dies should be performed to test the role of HCV geno-
type 1b in the silencing of socs1 transcription.
Methods
Patients
Consecutive patients with chronic HCV infection (n =5 9 )
were selected from the Gastroenterology Service of the
High Specialty Medical Unit, Mexican Institute of Social
Security in Puebla, Mexico. Blood samples were obtained
from April 2008 to August 2009. Inclusion criteria were
patients of both genders, age range 20-69 years, abnormal
ALT levels, positive to anti-HCV antibodies and detectable
HCV RNA in serum. Patients were clinically evaluated,
and laboratory tests were performed to identify stage of
liver disease. Patients coinfected with HIV, HBV or other
hepatitis viruses were excluded from the study; samples
with scarce RNA were also excluded. Clinically healthy
individuals with normal ALT values and negative tests for
HCV infection and other viral diseases were selected for
the non-infected individuals (n = 17).
HCV-infected patients (n = 48) were treated with a
combination of pegylated IFN-a 2a (180 μg/week) and
ribavirin (1000-1200 mg/day, Roche) for 48 weeks; in
accordance with the hospital management rules. Eleven
infected patients were analyzed prior to treatment and
were considered as untreated (U) for this study. Viral
loads were monitored in all infected patients with a per-
iodicity of 6 months. Response to IFN therapy was
determined on the basis of viral load reduction or virus
clearance at 6 months after treatment end.
The study was carried out in accordance with ethical
regulations approved by the institutional committee and
in accordance with the Declaration of Helsinki.
RNA extraction
Blood samples were centrifuged at 1000 × g for 20 min
and leukocyte bands were extracted and treated with
red blood cell lysis buffer (0.15 M ammonium chloride,
10 mM KHCO3,0 . 1m MN a 2 E D T A )a t4 ° Cf o r1 5m i n
and centrifuged at 480 × g for 4 min. This procedure
was repeated three times. Remaining white cells were
washed once with phosphate-buffered saline solution.
RNA was extracted from PBMCs with Trizol reagent
(Invitrogen, Carlsbad, CA, USA) following conventional
procedures. RNA was air dried and treated with DNAse
I (Fermentas, Glen Burnie, MD, USA). RNA concentra-
tion and quality were determined by spectrophotometry
and visualized by 1% agarose gel electrophoresis with
ethidium bromide.
Real-time RT-PCR for ifnar1
All RT-PCR were set up in 96-well optical plates using 4
ng of patients’ RNA, 10 μl TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems, Foster City, CA, USA),
and 1 μl of primers/probe set containing 900 nM of for-
ward (5′-GCTTTGGATGGTTTAAGCTTTACATA-
TAGC-3′), and reverse primers (5′-TCTGGTGAGA
GTTTATAAATTTTATGTCTGGAAT-3′), and 300 nM
probe [FAM]CTTCAGGTGTAGAAGAAAG[NFQ] was
added to a final volume of 20 μl per reaction. Hprt was
used as housekeeping gene. All samples were tested in
duplicate. RT-PCR program consisted of incubation at
48°C for 30 min, and 40 cycles at 95°C for 10 min, 95°C
for 15 sec, and 60°C for 1 min with the 7500 Real-Time
PCR System (Applied Biosystems).
CT and amplification efficiencies for target (ifnar1)
and housekeeping (hprt) genes were tested simulta-
neously and compared to demonstrate their equivalence.
Results were expressed in ΔCT, indeed target gene CT
minus housekeeping gene CT. After this, the compara-
tive method 2
-ΔΔCT was used for relative quantification
of ifnar1 transcription between study groups [30,31].
Real-time RT-PCR for socs1
Patients’ RNA samples were reverse-transcribed using
the random primers included in the Two-Step RT-PCR
Power SYBR Green Kit (Applied Biosystems). Reactions
were done at 25°C for 10 min, 48°C for 30 min and
95°C for 5 min. socs1 cDNA was amplified using
the Power SYBR Green Master Mix, 900 nM of forward
(5′-CACGCACTTCCGCACATTCC-3′) and reverse pri-
mers (5′-TCCAGCAGCTCGAAGAGGCA-3′), and 4 ng
RNA in a final volume of 20 μl. Then, 40 cycles were
carried out at 50°C for 2 min, 94°C for 10 min, 95°C for
2 min, 94°C for 1 min, 62°C for 30 sec and 72°C for 1
min. hprt was used as housekeeping gene. All reactions
were done in duplicate. Dissociation curves were con-
structed at 95°C for 15 sec, 60°C for 30 sec, 72°C for 1
min, 45°C for 15 sec and 60°C for 15 sec; socs1 expres-
sion was quantified by means of the comparative
method 2
-ΔΔCT as mentioned above.
Statistical analysis
Results expressed as 2
-ΔΔCT were reported as mean ±
standard deviation and were analyzed using one-way
ANOVA test. Differences between more than two
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tions between epidemiological variables were analyzed
by the Spearman test using ΔCT values. P values < 0.05
were considered statistically significant.
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